Shanghai Fudan-Zhangjiang 
Welcome,         Profile    Billing    Logout  
 4 Products   0 Diseases  4 Products   2 Trials   18 News 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
aminolevulinic acid (ALA PDT) / Shanghai Fudan-Zhangjiang
ChiCTR1800019213: 5-aminolevulinic acid photodynamic therapy in the treatment of non-melanoma skin cancer and precursor lesions in Chinese Patients

Recruiting
4
300
 
photodynamic therapy
Peking University First Hospital; Level of the institution:, The drug are partly donated by Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd.
non-melanoma skin cancer and precursor lesions
 
 
NCT06417281: Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid(5-ALA)

Recruiting
3
80
RoW
5 Aminolevulinic Acid
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
5-aminolevulinic Acid, Malignant Glioma of Brain
08/25
08/25
NCT06439433: ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Completed
2
119
RoW
Aminolaevulinic acid (500-mg bottle), ALA 500mg, Aminolaevulinic acid (750-mg bottle), ALA 750mg, Placebo
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Cervical Intraepithelial Neoplasia Grade 2, Papillomavirus Infections, p16 Protein
12/23
03/24
ChiCTR1800016755: A single dose tolerance and local pharmacokinetic study of topical Aminolevulinic acid hydrochloride in patients with cervical intraepithelial neoplasia (CIN)

Completed
1
42
 
Different concentrations of aminolevulinic acid (ALA) were applied to the surface of the cervix. Fluorescence intensity testing was performed at different time points after application.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.; Level of the institution:, The sponsor self-raised
CIN
 
 
dabigatran etexilate mesylate oral suspension (WD-1602) / Shanghai Fudan-Zhangjiang, China NT Pharma
NCT04592822: A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

Not yet recruiting
1
20
NA
WD-1602, Pradaxa®
Hong Kong WD Pharmaceutical Co., Limited
Anticoagulant
06/21
12/21
F0024 / Shanghai Fudan-Zhangjiang
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Recruiting
3
350
RoW
FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer
08/26
06/27
F0024-101, NCT05174637: A Study of FDA018-ADC in Patients with Advanced Solid Tumors

Active, not recruiting
1
78
RoW
FDA018-ADC, FDA018-Antibody-drug Conjugate
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced/ Metastatic Solid Tumors
12/29
12/29
F0002-ADC / Shanghai Fudan-Zhangjiang
NCT03894150: A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

Completed
1
45
RoW
F0002-ADC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Refractory or Recurrent CD30+ Hematologic Malignancies
07/20
03/24
FZJ-003 / Shanghai Fudan-Zhangjiang
NCT04715529: Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers

Completed
1
62
RoW
FZJ-003, Placebo
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Healthy Volunteers
07/22
07/22
FDA022-BB05 / Shanghai Fudan-Zhangjiang
NCT06413615: A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors

Recruiting
2
150
RoW
FDA022-BB05
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced Solid Tumor
07/25
06/26
NCT05564858: A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors

Recruiting
1
107
RoW
FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia, FDA022-BB05, FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced Solid Tumors
09/25
11/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
aminolevulinic acid (ALA PDT) / Shanghai Fudan-Zhangjiang
ChiCTR1800019213: 5-aminolevulinic acid photodynamic therapy in the treatment of non-melanoma skin cancer and precursor lesions in Chinese Patients

Recruiting
4
300
 
photodynamic therapy
Peking University First Hospital; Level of the institution:, The drug are partly donated by Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd.
non-melanoma skin cancer and precursor lesions
 
 
NCT06417281: Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid(5-ALA)

Recruiting
3
80
RoW
5 Aminolevulinic Acid
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
5-aminolevulinic Acid, Malignant Glioma of Brain
08/25
08/25
NCT06439433: ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Completed
2
119
RoW
Aminolaevulinic acid (500-mg bottle), ALA 500mg, Aminolaevulinic acid (750-mg bottle), ALA 750mg, Placebo
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Cervical Intraepithelial Neoplasia Grade 2, Papillomavirus Infections, p16 Protein
12/23
03/24
ChiCTR1800016755: A single dose tolerance and local pharmacokinetic study of topical Aminolevulinic acid hydrochloride in patients with cervical intraepithelial neoplasia (CIN)

Completed
1
42
 
Different concentrations of aminolevulinic acid (ALA) were applied to the surface of the cervix. Fluorescence intensity testing was performed at different time points after application.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.; Level of the institution:, The sponsor self-raised
CIN
 
 
dabigatran etexilate mesylate oral suspension (WD-1602) / Shanghai Fudan-Zhangjiang, China NT Pharma
NCT04592822: A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

Not yet recruiting
1
20
NA
WD-1602, Pradaxa®
Hong Kong WD Pharmaceutical Co., Limited
Anticoagulant
06/21
12/21
F0024 / Shanghai Fudan-Zhangjiang
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Recruiting
3
350
RoW
FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer
08/26
06/27
F0024-101, NCT05174637: A Study of FDA018-ADC in Patients with Advanced Solid Tumors

Active, not recruiting
1
78
RoW
FDA018-ADC, FDA018-Antibody-drug Conjugate
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced/ Metastatic Solid Tumors
12/29
12/29
F0002-ADC / Shanghai Fudan-Zhangjiang
NCT03894150: A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

Completed
1
45
RoW
F0002-ADC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Refractory or Recurrent CD30+ Hematologic Malignancies
07/20
03/24
FZJ-003 / Shanghai Fudan-Zhangjiang
NCT04715529: Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers

Completed
1
62
RoW
FZJ-003, Placebo
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Healthy Volunteers
07/22
07/22
FDA022-BB05 / Shanghai Fudan-Zhangjiang
NCT06413615: A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors

Recruiting
2
150
RoW
FDA022-BB05
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced Solid Tumor
07/25
06/26
NCT05564858: A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors

Recruiting
1
107
RoW
FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia, FDA022-BB05, FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced Solid Tumors
09/25
11/25

Download Options